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Abstract PDZ motifs are small protein-protein interaction 
modules that are thought to play a role in the clustering of 
submem bra nous signalling molecules. The specificity and func­
tional consequences of their associative actions is still largely 
unknown. Using two-hybrid methodology we here demonstrate 
that the PDZ motif of neuronal nitric oxide synthase (nNOS) 
can mediate the binding to several other proteins in brain. 
Peptide library screening showed that proteins bearing a 
carboxy-terminal G(D,E)XV* sequence are preferred targets 
for the nNOS amino-terminal PDZ motif. Potential nNOS 
targets include a melanoma-associated antigen, cyclophilins and 
the alC-adrenergic receptor.
© 1997 Federation of European Biochemical Societies.
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1. Introduction
Protein-protein interactions are the crucial events in cellu­
la r  signaling mechanisms and are in many cases mediated via 
relatively small protein domains. The importance of such de­
fined binding modules came with the recognition of the SH2 
a n d  SH3 (src homology) motifs which were later shown to be 
very  specific binding domains for phosphotyrosine-containing 
peptides and proline-rich stretches [1]. Later, the PH (pleck- 
strin  homology), LIM (Lin-ll/lsl-l/Mec-3) and PTB (phos- 
photyrosine-binding) domain have been added to this list 
[1-5]. Most recently, the PDZ motif was recognized as a pro­
tein-binding module in proteins involved in submembranous 
signaling processes [6-13], This 90 amino acid sequence motif 
w a s  first called GLGF repeat, later renamed to DHR (for 
Discs-large Homologous Region) and only recently termed 
P D Z  motif (acronym of PSD-95/SAP90, a constituent of syn­
ap tic  junctions, the Drosophila discs-large tumor suppressor 
gene product Dig A, present in septate junctions, and ZO-1, 
th e  major protein component of tight junctions) [14—17]. The 
m o tif  was suggested to play a role in targeting the protein to 
th e  submembranous cytoskeleton or in regulating the intrinsic 
activity of the enzyme [18]. Currently, more than 50 different 
proteins are known to contain PDZ motifs [14,19,20]. Most of 
:hese proteins are involved in signal transduction events or 
Organization of cytoskeletal structures, all at or close to the 
Dlasma membrane.
Other demonstrations of protein-protein interactions that
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Abbreviations;  M A G U K , membrane-associated guanylate kinase; 
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are mediated by PDZ motifs have appeared recently. Several 
investigations reported on the recognition of a carboxy-termi- 
nal T/SXV* motif (where T is threonine, S is serine, X is any 
amino acid, V is valine, and the asterisk symbolizes the car­
boxyl end of the protein) by the PDZ domains in multiple 
members of the PSD-95/SAP90 family of membrane-associ­
ated guanylate kinases, MAGUKs [8,9,11]. The T/SXV* motif 
is found in a diverse series of receptor and channel proteins 
suggesting that PDZ-containing proteins may be widely in­
volved in membrane specialization by anchoring signaling 
molecules at specific subcellular sites [15,17]. The in vivo rele­
vance is evident form InctD, a PDZ-containing protein that is 
essential for negative feedback regulation of the light-acti­
vated signaling cascade in Drosophila photoreceptors by bind­
ing the TRP Ca2+ channel [6], Also, the carboxy-terminus of 
the adenomatous polyposis coli gene product APC was shown 
to be recognized by the second PDZ domain of the human 
homolog of the Drosophila tumor suppressor discs-large [13].
The X-ray crystallographic structure of the third PDZ mo­
tifs of hDlg alone and PSD-95 provided the basis for under­
standing the recognition of the T/SXV* carboxyterminal pep­
tide [21,22]. The peptide binds in a short groove on the 
surface of the PDZ motif and a prominent cavity, formed 
by conserved residues in the PDZ motif, stabilizes the carbox- 
ylate moiety [21], In addition, another mode of interaction by 
PDZ motifs was observed for hDlg PDZ-3; the domain forms 
a dimer in the crystal albeit that this interaction in solution 
appeared rather weak [22],
Neuronal nitric oxide synthase (nNOS) differs from the two 
other NOS family members (endothelial NOS and macro­
phage NOS) in having an N-terminal segment that harbors a 
PDZ motif [18] and it has been proposed that this single PDZ 
motif is responsible for the membrane targeting of nNOS [23]. 
Indeed it has been demonstrated that its N-terminal PDZ mo­
tif determines nNOS association with the sarcolemma in 
muscle through binding to the dystrophin complex [10]. In 
brain the submembranous localization o f  nNOS was inde­
pendent of the dystrophin complex [10]. To identify the pro­
tein-binding sites for the nNOS PDZ motif in brain tissue we 
used two-hybrid interaction trap methodology [24]. The con­
sensus sequence for carboxy-terminal peptides that are prefer­
entially bound by the nNOS PDZ motif was determined and 
used to predict potential nNOS-associated proteins in brain.
2. Materials and methods
2.1. Interaction-trap assay 
Plasmid DMAs and the yeast strain used for the interact ion-trap  
assay were provided by Drs. Finley, Brent and colleagues (M assachu­
setts General Hospital, Boston, M A) and used as described [24]. T he  
bait vector, which contains sequences encoding the protein o f  interest 
fused to the DNA-binding domain, prey vector,- containing inserts
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Table 1
Interactors o f  nNOS
Clone Accession number
= Human cD N A  clone 147773 5' (127) R 81609
-  Mouse cD N A  clone 605767 5' (321) AA 154912
= Human thyroid receptor interactor mRNA TRIP13 (375) L 40384
= Human thyroid receptor interactor mRNA TRIP 13 (157) L 40384
= Human cD N A  clone 45462 5' (477) H 10486
= Human cD N A  clone 530635 5' (91) AA 071112
= Human cD N A  clone 143050 5' (161) R 71284
=, Identical; ~ , 90% homologous. Between brackets the position o f the starting nucleotide of the obtained cD N A  in the database sequence entry is 
given.
encoding protein fused to the transcription activation domain, and 
lacZ reporter plasmid were introduced into yeast strain EGY48 by 
transformation. Interaction was tested on minimal agar plates lacking 
leucine, tryptophan, uracil and histidine, and containing 2% galactose, 
1% rafiinose and 80 pg/ml X-gal [24].
2.2. Generation o f  nNOS subclones
The full-length rat nNOS cDNA, cloned in plasmid pBluescript KS, 
was a gift o f  Dr. Snyder (Baltimore, MD). The insert o f subclone 
nNOS(aa 1-111) was generated by the polymerase chain reaction 
(PCR) using oligonucleotide primers nosl (5'-TTGAATTCTGAAG- 
GACAC AGAT ACC AT-3') and nos2 (5'-TAAGATCTGAAGGTG- 
GT CT CC AG AT G-3'). The amplified product was bhmt-ended with 
Klenow (large fragment) D NA  polymerase and subcloned in pEG202 
vector. Subclone nNOS(aa 1-195) is the product o f the amplification 
with primers nosl and nos3 (5'-TTTCTCGAGCATCATGTTCCCC- 
GATGT-3'). After digestion with iTctfRi, this fragment was blunt- 
ended with Klenow, digested with Xhol and also subcloned in 
pEG202 vector. The fragment nNOS(aa 99-418) that is missing the 
PDZ motif was excised from pBlue-nNOS using Apcil and UtiwHI 
restriction enzymes» blunt-ended and subcloned in pEG202.
2.3 . Generation of PSD-951SAP90, Fas and alC-adrenergic receptor 
sub clones
Total RNA was isolated using the LiCl/urea method [25]. SAP90 
cD N A  fragment was generated by reverse transcriptase (RT)-PCR as 
described [26]. Specific oligonucleotide primers SAP90-1 (5'-CCA- 
GATCTGCAGTGGAGGCCC-3') and SAP90-2 (5'-AGGCTCGAG- 
GTCCTTGGCCAC-3') were deduced from the published sequence
[27]. The amplification product was digested with BgUl and Xhol 
and subcloned in plasmid pJGBr2 (a modified prey vector) and a 
pEG202-derived bait vector.
Prey plasmid pJG-hFas was constructed by subcloning a blunt- 
ended B glll-A pal  fragment derived from pCMV-hFas (kindly pro­
vided by Dr. P. Anderson, Boston, MA) into the pJGBr2 interaction 
trap prey vector.
A cD N A  fragment encoding the last 114 amino acid residues o f  the 
rat alC-adrenergic receptor [28] was generated by reverse transcrip­
tase (RT)-PCR [26] using oligonucleotide primers alCAR-1 (5'- 
GGAATTCAAGCATGCCCTGGG-3') and alC A R -2 (5'-ATACTC- 
GAGCTAGACTTCCTCCCCGTT-3'). The PCR product was di­
gested with £coRI and Xhol and subcloned in the prey vector
p JG4-5.
2.4. Construction o f  peptide library
The sequences of the oligonucleotides used in the generation of the 
peptide library are 5'-CCGGATCC(NNB)2oCGAATTCC-3' (where 
N  is a mixture of A, G, C and T and B a mixture of G, T and C) 
and 5'-GGAATTCG~3' (for antisense priming). The primers were 
annealed at room temperature and filled in using Klenow (large frag­
ment) D N A  polymerase in the presence of 0.1 mM of each dNTP. 
After removal of unincorporated nucleotides and primers, the ampli­
fied product was digested with BamHl and EcoRl. After size-separa- 
tion on 4% NuSieve GTG agarose (FMC) the product was recovered 
from the agarose using Gelase (Biozym) and then precipitated. Sub­
sequently, the fragments were ligated in JBg/II-iscflRI-digested pJGBr2 
prey vector, transferred to TG-1 cells by electroporation and plated 
on TYE/glucose plates. The resulting library contained 8 X 10a inde­
pendent transformants of which 95% contained the peptide-encoding 
insert. Colonies on the plates were collected by scraping and plasmid 
D N A  was isolated using the Qiagen plasmid Mega Kit (Westburg).
2.5. DNA sequence analysis
Nucleotide sequences were determined by the double-stranded 
DNA dideoxy sequencing method using radioactive nucleotides [29] 
or by cycle sequencing employing fluorochrome-tagged primers ac­
cording to the manufacturer’s instructions (Amersham, UK). D N A  
sequence gel readings were analyzed using the GCG package [30] 
provided by the Dutch CAOS/CAMM Center, The OWL database 
(a nonredundant sum o f Swiss-Prot, PIR, GenBank and NRL-3D  
databases), release 29.1 (January 1997), was searched for 
-G(D,E,N)XV stop-containing proteins using FINDPATTERNS [30].
3. Results
In muscle tissue nNOS can be targeted to the dystrophin 
glycoprotein complex on the sarcolemma by virtue of its PDZ 
motif [10], In brain, a dystrophin glycoprotein complex is 
absent but still nNOS is localized submembranously [10] sug­
gestive of other nNOS targets in brain. Reasoning that the 
nNOS PDZ motif was responsible for the subcellular distri­
bution [23] we set out to clone the nNOS PDZ motif targets in 
brain using the two-hybrid interaction trap methodology [24], 
To this end, the rat nNOS PDZ motif (amino acids 1-111) as 
fused to the LexA DNA-binding domain and used as a bait to 
screen a human fetal brain cDNA library. Several interacting 
clones were obtained from 10G transfected yeast colonies and 
for most cDNAs the interaction could be confirmed after re- 
introduction of the involved plasmids in yeast. Subsequently, 
end~in sequencing of the isolated interacting cDNAs was per­
formed to enable screening of the nucleotide sequence data­
bases for possible homologies to known genes. The results are 
summarized in 'Table 1. Five clones appeared identical or 
homologous to expressed sequence tags (EST), database en­
tries . for which no functional data at the protein level are 
available. Also, two independent but overlapping cDNAs 
were isolated that encode a thyroid receptor interacting pro­
tein called TRIP 13 [31]. This suggests an nNOS PDZ-medi- 
ated submembranous docking of TRIP 13 and, consequently, 
of the thyroid receptor that is awaiting its ligand. After ste­
roid binding the receptor is released from TRIP 13 and could
Table 2
Neuronal NOS PDZ m otif specificity deduced through two-hybrid 
screening of a random peptide library
Peptide Sequence Interaction
1 GAGERGDSV* ++
2 YAGQWGESV* + + + +
3 GDAV* ++
4 RRWGDPV*
5 R. PAGNPV* ++
6 RGRDQRDDAV* +
Interaction results are reflected using plus and minus signs: ++++ , 
very strong binding; ++, strong binding; +, weak but significant 
interaction.
Table 3
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PD Z m otif specificity for distinct carboxyl-terminal peptide sequences
Preys Baits
NOS PDZ SAP90 PDZ2 PTP-BL PDZ2
Peptide 2 (-GSEV*) + + + + — —
hFAS (-QSLV*) — +
MAGE-11 (-GEGV*) + /— — —
a lC -A R  (-GEEV*) H— — —
Empty pJG vector — — —
Interaction results are reflected using plus and minus signs: + + + + , very strong interaction; + + , strong interaction; +, weak but significant 
interaction; + / - ,  very weak interaction; —, no interaction detectable.
move to the nucleus to perform its role as a transcription 
factor. Such a model does not unravel, however, the mecha­
nism by which nNOS itself is targeted to the submembranous 
space in brain cells. Perhaps PDZ motifs can mediate multiple 
interactions simultaneously, which would imply independent 
binding interfaces on this small protein domain.
As an alternative strategy to identify target sites for nNOS 
we constructed a library that directed the synthesis in yeast of 
constrained peptides of random sequences fused to the protein 
moiety encoded by the interaction trap prey vector and 
screened it using the nNOS PDZ motif as a bait. Oligonucleo­
tides were used to produce DNA fragments harboring 20 ran­
dom codons of the type NNB (N is any nucleotide; B is G, C, 
or T) flanked by BamHl and EcoR.1 sites. The codon bias was 
chosen in such a way that two-thirds of the encoding oligonu­
cleotides would lack internal stop codons. The resulting li­
brary contained 8 x 1 0 s individual recombinants. From 
0.25X10° yeast transformants, we isolated six plasmids that 
encoded peptides interacting with the nNOS PDZ motif (Table 
2) but not with control proteins. From these peptide sequences 
a C-terminal consensus target site, -G(D,E)XV*, emerged.
We next investigated the sequence specificity in the nNOS 
PDZ-mediated interaction in a two-hybrid assay using different 
baits (Table 3). The nNOS PDZ motif, which has a strong 
affinity for the peptide GESV*, does not interact with the 
(T,S)XV* MAGUK target sequence as present in human 
Fas. The second PDZ motif of the MAGUK protein PSD-95 
does bind to this hFas C-terminal peptide (Table 3). The same 
holds true for the PTP-BL PDZ motif that was reported to 
bind to human Fas [12]. Both PDZ motifs, however, failed to 
interact with the nNOS PDZ-specific peptide GESV* (Table 3).
To look for proteins that do contain a G(D,E,N)XV* car- 
boxyterminus and thus are prime candidates for nNOS-asso- 
ciated proteins, we performed a database search and identified 
four different types of mammalian proteins. The liver-specific 
nuclear protein acylneuraminate cytidylyl transferase (acc. no. 
P29188; carboxy-terminal sequence -GNGV*) from rat was 
considered not relevant on the basis of its restricted localiza­
tion. The other mammalian proteins were the human melano­
ma-associated antigen MAGE-11 (acc. no. P43364; sequence
Table 4
Binding o f  nNOS to the SAP90 PDZ2 m otif requires sequences C- 
terminal o f  the nNOS PD Z  m otif
Bait Prey; SAP90-PDZ 2 Prey: liFAS
nN O S (amino acid 1-111) — —
nN O S (1-195) + + —
nN O S (99-418) — —
SAP90-PD Z 2 N D +
Interaction results are reflected using plus and minus signs: ++ , 
strong binding; +, weak but significant interaction; —, no interaction 
detectable. N D , not determined.
-GEGV*), the ex 1-adrenergic receptor (AR) subtype C (acc. 
no. P43140; sequence -GEEV*), and peptidylprolyl isomerases 
or cyclophilins (acc. no. S61070 and S66681; sequence 
-GEYV*). To test these predicted interactions a MAGE-11- 
encoding prey clone (available through an unrelated two-hy- 
brid screen; W.H.A, van den Maagdenberg, B. Pepers; un­
published data) and the carboxyterminal tail of the rat oclC- 
AR were used in the interaction trap assay. Indeed we could 
observe a weak interaction for MAGE-11 and a strong one 
for cilG-AR with the nNOS PDZ motif (Table 3).
In our search for submembranous nNOS-associating pro­
teins in brain we did not obtain MAGUK-encoding cDNA 
clones as reported by Bredt and co workers [7]. They described 
the binding of the second PDZ motif of PSD-95/SAP90 and 
of the related protein PSD-93 to amino acids 1-195 of nNOS, 
suggestive of PDZ-PDZ homotypic interactions. The nNOS 
fragment that was used in their experiment spans not only the 
PDZ motif (as in our study; residues 1-111) but contains an 
additional 87 residues C-tenninally. Thus, the observed inter­
actions of nNOS with PSD-95/SAP90 and PSD-93 could be 
mediated through binding of stretches just C-terminal of the 
nNOS PDZ motif, spanning residues 112-195. To investigate 
this possibility we generated a cDNA fragment encoding the 
second PDZ motif of PSD-95 by RT-PCR on brain mRNA 
and inserted the fragment into the interaction trap prey vec­
tor. Subsequently, various nNOS N-terminal fragments were 
produced as baits for two-hybrid analysis (Table 4). The ex­
periment showed that no interaction with PSD-95 PDZ-2 is 
observed for the nNOS PDZ motif alone (aa 1-111). Also, no 
binding with PSD-95 was found if only the additional 84 
residues just C-terminal of the PDZ domain were present. 
By contrast, employing the entire stretch of 195 N-terminal 
residues of nNOS (including the PDZ motif) in the two-hybrid 
assay resulted in an interaction with the second PSD-95 PDZ 
motif (Table 4).
4. Discussion
It is becoming increasingly clear that PDZ motifs are well- 
tailored to bind to the carboxy-termini of proteins 
[15,17 ,20 ,32 ,33 ]- Use of the oriented peptide library technique 
has resulted in a catalogue of unique optimal sequences for 
multiple individual PDZ motifs, defined primarily by the car­
boxyl terminal three to seven residues of the target peptide
[34]. Using two-hybrid methodology we have identified the 
carboxyterminal consensus sequence that is recognized specif­
ically by the neuronal NOS PDZ motif (Table 2). This target 
site differs from the ones determined for mouse discs-Large, 
PTP-BAS, p55, LIN-2, Tiam-1, and AF-6 [34] and the 
(T,S)XV* peptide recognized by MAGUK family member 
PDZ motifs [15,17]. Carboxyterminal sequence recognition,
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however, cannot explain the observed interaction between 
nNOS and PSD-95/SAP90 [7] and also a pure PDZ-PDZ ho- 
motypic interaction can be excluded (Table 4). As a matter of 
fact, using a variety of PDZ motifs in the interaction trap 
assay, including those of PSD-95, nNOS and PTP-BL [19], 
we have never observed any significant PDZ-PDZ association 
(data not shown). Nevertheless, the affinity of PSD-95 PDZ 
motif 2 for an nNOS internal protein segment convincingly 
demonstrates that PDZ-mediated interactions are not limited 
to C-terminal peptide recognition only.
We re-examined the clones isolated from the brain cDNA 
library using the nNOS PDZ motif (Table I) for the carbox- 
yterminal sequence they encoded but this was hampered by 
the limited sequence data that are available for EST s. No 3' 
sequence entries have been deposited in the database for the 
EST cDNA clones 605767 and 143050. For EST clones 
147773, 45462 and 530635 sequences have been determined 
at the 3' end (acc. nrs. R81352, H09728 and AA071113) 
but, provided that coding sequences are at all present in these 
3' sequence segments, no G(D,E,N)XV*-like carboxyterminus 
was found. Also the TRIP 13 carboxyterminus (-LSLA*) lacks 
homology to the peptide target binding site preferred by the 
nNOS PDZ motif.
A database search with the preferred nNOS PDZ target site 
revealed three interesting candidate partner proteins; the mel­
anoma-associated antigen 11, cyclophilins and the alC-adre- 
nergic receptor (Table 3). The human melanoma-associated 
antigen MAGE-11 is a member of a large family of tumor 
rejection antigens that are normally only expressed in testis 
and placenta. The cellular function of this protein class is 
completely obscure and, in combination with the highly re­
stricted expression profile, precludes a further discussion. 
The prototype members of the cis-trans peptidyl-prolyl isom- 
erases, cyclophilm A and FKBP12, were discovered on the 
basis of their ability to bind and mediate the immunosuppres­
sive effects of the drugs cyclosporin, FK506 and rapamycin. 
Cyclophylin is localized submembranously and in brain cyclo­
sporin blocks the IL-2-induced release of CRH (corticotropin- 
releasing hormone) by preventing the dephosphorylation and 
thus activation of nNOS [35]* This would, however, not re­
quire a direct interaction between the cyclophylin carboxy-ter- 
minal tail and nNOS, and can be explained by the cyclospor- 
in-cyclophylin complex binding to calcineurin, the calcium- 
dependent protein phosphatase that should dephosphorylate 
»
nNOS [36], Finally, the a  1-adrenergic receptor (AR) subtype 
C is expressed in multiple tissues including brain and its car- 
boxy terminal tail of the rat alC-AR strongly and specifically 
interacted with the nNOS PDZ motif (Table 3). Interestingly, 
NOS is heavily involved in the regulation of hormone and 
neuropeptide release in different areas of the brain and is act­
ing downstream of the al-AR in certain signaling pathways 
[37,38]. A physical link between the al-AR and NOS would be 
an ideal setting for such a signal cascade and, moreover, might 
explain why inhibition of NOS does not affect a 2-AR signal­
ing [39]. The interaction of the nNOS PDZ motif and the alC- 
AR reported here now enables to test the occurrence in vivo 
and, of course, to determine its functional implications.
Acknowledgements: We thank Drs. Solomon H. Snyder and Sarnie R. 
Jaffrey for the rat neuronal NOS cDNA and communicating results 
prior to publication. We gratefully acknowledge Drs. R. Finley and 
R. Brent for generously providing us with the interaction trap strains 
and plasmids, and Dr. P. Anderson for providence of the pCMV-hFas
construct. Biocomputing facilities were provided by the Dutch CAOS/ 
CAMM Center.
References
[1] T. Pawson, Nature 373 (1995) 573-580.
[2] G.B. Cohen, R. Ren, D . Baltimore, Cell 80 (1995) 237-248.
[3] M.A. Lemmon, K.M. Ferguson, J. Schlessinger, Cell 85 (1996) 
621-624.
[4] I.B. Dawid, R. Toyama, M. Taira, C.R. Acad. Sei. 318 (1995) 
295-306.
[5] M.J. Eck, Curr. Biol. 3 (1995) 421-424.
[6] B.H. Shieh, M .Y. Zhu, Neuron 16 (1996) 991-998.
[7] I.E. Brenman, D.S. Chao, S.H. Gee, A.W, McGee, S.E. Craven, 
D.R. Santillano, Z. Wu, F. Huang, H. Xia, M.F. Peters, S.C. 
Froehner, D,S. Bredt, Ceil 84 (1996) 757-767.
[8] M. Niethammer, E. Kim, M. Sheng, J. Neurosci. 16 (1996) 2157- 
2163.
[9] E. Kim, M. Niethammer, A, Rothschild, Y.N. Jan, M. Sheng, 
Nature 378 (1995) 85-88.
[10] J.E. Brenman, D.S. Chao, H. Xia, K. Aldape, D.S. Bredt, Cell 82
(1995) 743-752.
[11] H.C. Kornau, L.T. Schenker, M .B. Kennedy, P.H. Seeburg, Sci­
ence 269 (1995) 1737-1740.
[12] T  Sato, S. Irie, S. Kitada, J.C. Reed, Science 268 (1995) 411-415.
[13] A. Matsumine, A. Ogai, T. Senda, N . Okumura, K. Satoh, G.-H, 
Baeg, T. Kawahara, S. Kobayashi, M. Okada, K. Toyoshima, T. 
Akiyama, Science 272 (1996) 1020-1023.
[14] C.P. Ponting, C. Phillips, Trends Biochem. Sei. 20 (1995) 102- 
103.
[15] S.N. Gomperts, Cell 84 (1996) 659-662.
[16] S.K. Kim, Curr, Opin. Cell Biol. 7 (1995) 641-649.
[17] M. Sheng, Neuron 17 (1996) 575-578.
[18] K.-O. Cho, C.A. Hunt, M.B. Kennedy, Neuron 9 (1992) 929- 
942.
[19] W. Hendriks, J. Schepens, D. Bachner, J, Rijss, P. Zeeuwen, U. 
Zechner, H, Hameister, B. Wieringa, J. Cell. Biochem. 59 (1995) 
418-430.
[20] A.S. Fanning, J.M. Anderson, Curr, Biol. 6 (1996) 1385-1388.
[21] D.A. Doyle, A. Lee, J, Lewis, E. Kim, M. Sheng, R. MacKin­
non, Cell 85 (1996) 1067-1076.
[22] J.H. Morais Cabral, C. Petrosa, M.J. Sutcliffe, S. Raza, O. By­
ron, F. Poy, S.M. Marfatia, A .H , Chishti, R.C. Liddington, Na­
ture 382 (1996) 649-652.
[23] W. Hendriks, Biochem. J. 305 (1995) 687-688.
[24] J. Gyuris, E. Golemis, H . Chertkov, R. Brent, Cell 75 (1993) 
791-803.
[25] C  Auifray, F. Rougeon, Eur. J. Biochem. 107 (1980) 303-314.
[26] W. Hendriks, C. Brugman, J. Schepens, B. Wieringa, Mol. Biol. 
Rep. 19 (1994) 105-108.
[27] U. Kistner, B.M. Wenzel, R.W . Veh, C. Cases-Langhoff, A.M. 
Garner, TJ. Appeltauer, B. Voss, E.D. Gundelfinger, C.C, Gar­
ner, J. Biol. Chem. 268 (1993) 4580-4583,
[28] T.M. Laz, C. Forray, K.E. Smith, J,A. Bard, P.J. Vaysse, T.A. 
Branchek, R.L. Weinshank, M ol. Pharmacol. 46 (1994) 414-  
422.
[29] M. Hattori, Y. Sakaki, Anal. Biochem. 152 (1986) 232-238.
[30] J. Devereux, P. Haeberli, O. Smithies, Nucl. Acids Res. 12 (1984) 
387-395.
[31] J.W. Lee, H.S. Choi, J. Gyuris, R. Brent, D.D. Moore, Mol. 
Endocrinol. 9 (1995) 243-254. ■
[32] S.C. Harrison, Cell 86 (1996) 341-343.
[33] D. Cowburn, Structure 4 (1996) 1005-1008.
[34] Z. Songyang, A.S. Fanning, C. Fu, J. Xu, S.M. Marfatia, A.H. 
Chishti, A. Crompton, A.C. Chan, J.M. Anderson, L.C. Cantley, 
Science 275 (1997) 73-77.
[35] S. Karanth, K. Lyson, S.M. McCann, Neuroimmunomodulation
1 (1994) 82-85.
[36] T.M. Dawson, J.P. Steiner, W.E. Lyons, M. Fotuhi, M. Blue, 
S.H. Snyder, Neuroscience 62 (1994) 569-580.
[37] G. Canteros, V. Rettori, A. Genaro, A. Suburo, M. Gimeno,
S.M. McCann, Proc. Natl. Acad. Sei. USA 93 (1996) 4246-4250.
[38] J, Raber, F.E. Bloom, J. Neurosci. 14 (1994) 6187-6195.
[39] R.W. McPherson, J.R. Kirsch, R.J. Traystman, Anesth. Analg. 
78 (1994) 67-72.
